Dr Stephen Pelsue, Science Director, joins BBI Solutions as part of the recent acquisition of Maine Biotechnology Services (MBS). Dr Pelsue provides technical expertise and leadership to the Antibody Development Services scientific team as they work to integrate new tools, technologies and processes that enhance our ability to address challenging new antibody targets on behalf of our client base.
The in vitro diagnostics (IVD) market is constantly evolving and currently there is a shift towards the need for lower limits of analyte detection. Lower assay sensitivities are required to detect trace amounts of a biomarker within an assay.
The BBI Group has just moved to a new £14m global headquarters in Crumlin, South Wales, UK. Mario Gualano is the new CEO and here he talks about the benefits the investment will bring to customers.
David Fraser, Product Manager for Lateral Flow Services and Detection has 14 years’ experience in the in vitro diagnostics (IVD) market. In his new role David will be championing BBI Solutions’ lateral flow products and services.
Quality raw materials are the base that all great products depend on, but surprisingly, this is part of the process that many companies - particularly those launching a new product or exploring a new direction - take for granted and fail to investigate thoroughly enough.
A good partnership is the cornerstone of most successful businesses, it’s often the catalyst that brings original ideas to life and transforms concept to reality. Nikki Robinson, Head of Reagents explains how our custom conjugation scientists are an expert team that deeply understands the power of partnership.
The patent pending, Morffi signal enhancement technology has marked a successful first year since launch.